Cargando…
A Comprehensive Strategy to Evaluate Compatible Stability of Chinese Medicine Injection and Infusion Solutions Based on Chemical Analysis and Bioactivity Assay
Stability of traditional Chinese medicine injection (TCMI) is an important issue related with its clinical application. TCMI is composed of multi-components, therefore, when evaluating TCMI stability, several marker compounds cannot represent global components or biological activities of TCMI. Till...
Autores principales: | , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5694823/ https://www.ncbi.nlm.nih.gov/pubmed/29187820 http://dx.doi.org/10.3389/fphar.2017.00833 |
_version_ | 1783280207564636160 |
---|---|
author | Li, Jian-Ping Liu, Yang Guo, Jian-Ming Shang, Er-Xin Zhu, Zhen-Hua Zhu, Kevin Y. Tang, Yu-Ping Zhao, Bu-Chang Tang, Zhi-Shu Duan, Jin-Ao |
author_facet | Li, Jian-Ping Liu, Yang Guo, Jian-Ming Shang, Er-Xin Zhu, Zhen-Hua Zhu, Kevin Y. Tang, Yu-Ping Zhao, Bu-Chang Tang, Zhi-Shu Duan, Jin-Ao |
author_sort | Li, Jian-Ping |
collection | PubMed |
description | Stability of traditional Chinese medicine injection (TCMI) is an important issue related with its clinical application. TCMI is composed of multi-components, therefore, when evaluating TCMI stability, several marker compounds cannot represent global components or biological activities of TCMI. Till now, when evaluating TCMI stability, method involving the global components or biological activities has not been reported. In this paper, we established a comprehensive strategy composed of three different methods to evaluate the chemical and biological stability of a typical TCMI, Danhong injection (DHI). UHPLC-TQ/MS was used to analyze the stability of marker compounds (SaA, SaB, RA, DSS, PA, CA, and SG) in DHI, UHPLC-QTOF/MS was used to analyze the stability of global components (MW 80–1000 Da) in DHI, and cell based antioxidant capability assay was used to evaluate the bioactivity of DHI. We applied this strategy to assess the compatible stability of DHI and six infusion solutions (GS, NS, GNS, FI, XI, and DGI), which were commonly used in combination with DHI in clinic. GS was the best infusion solution for DHI, and DGI was the worst one based on marker compounds analysis. Based on global components analysis, XI and DGI were the worst infusion solutions for DHI. And based on bioactivity assay, GS was the best infusion solution for DHI, and XI was the worst one. In conclusion, as evaluated by the established comprehensive strategy, GS was the best infusion solution, however, XI and DGI were the worst infusion solutions for DHI. In the compatibility of DHI and XI or DGI, salvianolic acids in DHI would be degraded, resulting in the reduction of original composition and generation of new components, and leading to the changes of biological activities. This is the essence of instability compatibility of DHI and some infusion solutions. Our study provided references for choosing the reasonable infusion solutions for DHI, which could contribute the improvement of safety and efficacy of DHI. Moreover, the established strategy may be applied for the compatible stability evaluation of other TCMIs. |
format | Online Article Text |
id | pubmed-5694823 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2017 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-56948232017-11-29 A Comprehensive Strategy to Evaluate Compatible Stability of Chinese Medicine Injection and Infusion Solutions Based on Chemical Analysis and Bioactivity Assay Li, Jian-Ping Liu, Yang Guo, Jian-Ming Shang, Er-Xin Zhu, Zhen-Hua Zhu, Kevin Y. Tang, Yu-Ping Zhao, Bu-Chang Tang, Zhi-Shu Duan, Jin-Ao Front Pharmacol Pharmacology Stability of traditional Chinese medicine injection (TCMI) is an important issue related with its clinical application. TCMI is composed of multi-components, therefore, when evaluating TCMI stability, several marker compounds cannot represent global components or biological activities of TCMI. Till now, when evaluating TCMI stability, method involving the global components or biological activities has not been reported. In this paper, we established a comprehensive strategy composed of three different methods to evaluate the chemical and biological stability of a typical TCMI, Danhong injection (DHI). UHPLC-TQ/MS was used to analyze the stability of marker compounds (SaA, SaB, RA, DSS, PA, CA, and SG) in DHI, UHPLC-QTOF/MS was used to analyze the stability of global components (MW 80–1000 Da) in DHI, and cell based antioxidant capability assay was used to evaluate the bioactivity of DHI. We applied this strategy to assess the compatible stability of DHI and six infusion solutions (GS, NS, GNS, FI, XI, and DGI), which were commonly used in combination with DHI in clinic. GS was the best infusion solution for DHI, and DGI was the worst one based on marker compounds analysis. Based on global components analysis, XI and DGI were the worst infusion solutions for DHI. And based on bioactivity assay, GS was the best infusion solution for DHI, and XI was the worst one. In conclusion, as evaluated by the established comprehensive strategy, GS was the best infusion solution, however, XI and DGI were the worst infusion solutions for DHI. In the compatibility of DHI and XI or DGI, salvianolic acids in DHI would be degraded, resulting in the reduction of original composition and generation of new components, and leading to the changes of biological activities. This is the essence of instability compatibility of DHI and some infusion solutions. Our study provided references for choosing the reasonable infusion solutions for DHI, which could contribute the improvement of safety and efficacy of DHI. Moreover, the established strategy may be applied for the compatible stability evaluation of other TCMIs. Frontiers Media S.A. 2017-11-15 /pmc/articles/PMC5694823/ /pubmed/29187820 http://dx.doi.org/10.3389/fphar.2017.00833 Text en Copyright © 2017 Li, Liu, Guo, Shang, Zhu, Zhu, Tang, Zhao, Tang and Duan. http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Pharmacology Li, Jian-Ping Liu, Yang Guo, Jian-Ming Shang, Er-Xin Zhu, Zhen-Hua Zhu, Kevin Y. Tang, Yu-Ping Zhao, Bu-Chang Tang, Zhi-Shu Duan, Jin-Ao A Comprehensive Strategy to Evaluate Compatible Stability of Chinese Medicine Injection and Infusion Solutions Based on Chemical Analysis and Bioactivity Assay |
title | A Comprehensive Strategy to Evaluate Compatible Stability of Chinese Medicine Injection and Infusion Solutions Based on Chemical Analysis and Bioactivity Assay |
title_full | A Comprehensive Strategy to Evaluate Compatible Stability of Chinese Medicine Injection and Infusion Solutions Based on Chemical Analysis and Bioactivity Assay |
title_fullStr | A Comprehensive Strategy to Evaluate Compatible Stability of Chinese Medicine Injection and Infusion Solutions Based on Chemical Analysis and Bioactivity Assay |
title_full_unstemmed | A Comprehensive Strategy to Evaluate Compatible Stability of Chinese Medicine Injection and Infusion Solutions Based on Chemical Analysis and Bioactivity Assay |
title_short | A Comprehensive Strategy to Evaluate Compatible Stability of Chinese Medicine Injection and Infusion Solutions Based on Chemical Analysis and Bioactivity Assay |
title_sort | comprehensive strategy to evaluate compatible stability of chinese medicine injection and infusion solutions based on chemical analysis and bioactivity assay |
topic | Pharmacology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5694823/ https://www.ncbi.nlm.nih.gov/pubmed/29187820 http://dx.doi.org/10.3389/fphar.2017.00833 |
work_keys_str_mv | AT lijianping acomprehensivestrategytoevaluatecompatiblestabilityofchinesemedicineinjectionandinfusionsolutionsbasedonchemicalanalysisandbioactivityassay AT liuyang acomprehensivestrategytoevaluatecompatiblestabilityofchinesemedicineinjectionandinfusionsolutionsbasedonchemicalanalysisandbioactivityassay AT guojianming acomprehensivestrategytoevaluatecompatiblestabilityofchinesemedicineinjectionandinfusionsolutionsbasedonchemicalanalysisandbioactivityassay AT shangerxin acomprehensivestrategytoevaluatecompatiblestabilityofchinesemedicineinjectionandinfusionsolutionsbasedonchemicalanalysisandbioactivityassay AT zhuzhenhua acomprehensivestrategytoevaluatecompatiblestabilityofchinesemedicineinjectionandinfusionsolutionsbasedonchemicalanalysisandbioactivityassay AT zhukeviny acomprehensivestrategytoevaluatecompatiblestabilityofchinesemedicineinjectionandinfusionsolutionsbasedonchemicalanalysisandbioactivityassay AT tangyuping acomprehensivestrategytoevaluatecompatiblestabilityofchinesemedicineinjectionandinfusionsolutionsbasedonchemicalanalysisandbioactivityassay AT zhaobuchang acomprehensivestrategytoevaluatecompatiblestabilityofchinesemedicineinjectionandinfusionsolutionsbasedonchemicalanalysisandbioactivityassay AT tangzhishu acomprehensivestrategytoevaluatecompatiblestabilityofchinesemedicineinjectionandinfusionsolutionsbasedonchemicalanalysisandbioactivityassay AT duanjinao acomprehensivestrategytoevaluatecompatiblestabilityofchinesemedicineinjectionandinfusionsolutionsbasedonchemicalanalysisandbioactivityassay AT lijianping comprehensivestrategytoevaluatecompatiblestabilityofchinesemedicineinjectionandinfusionsolutionsbasedonchemicalanalysisandbioactivityassay AT liuyang comprehensivestrategytoevaluatecompatiblestabilityofchinesemedicineinjectionandinfusionsolutionsbasedonchemicalanalysisandbioactivityassay AT guojianming comprehensivestrategytoevaluatecompatiblestabilityofchinesemedicineinjectionandinfusionsolutionsbasedonchemicalanalysisandbioactivityassay AT shangerxin comprehensivestrategytoevaluatecompatiblestabilityofchinesemedicineinjectionandinfusionsolutionsbasedonchemicalanalysisandbioactivityassay AT zhuzhenhua comprehensivestrategytoevaluatecompatiblestabilityofchinesemedicineinjectionandinfusionsolutionsbasedonchemicalanalysisandbioactivityassay AT zhukeviny comprehensivestrategytoevaluatecompatiblestabilityofchinesemedicineinjectionandinfusionsolutionsbasedonchemicalanalysisandbioactivityassay AT tangyuping comprehensivestrategytoevaluatecompatiblestabilityofchinesemedicineinjectionandinfusionsolutionsbasedonchemicalanalysisandbioactivityassay AT zhaobuchang comprehensivestrategytoevaluatecompatiblestabilityofchinesemedicineinjectionandinfusionsolutionsbasedonchemicalanalysisandbioactivityassay AT tangzhishu comprehensivestrategytoevaluatecompatiblestabilityofchinesemedicineinjectionandinfusionsolutionsbasedonchemicalanalysisandbioactivityassay AT duanjinao comprehensivestrategytoevaluatecompatiblestabilityofchinesemedicineinjectionandinfusionsolutionsbasedonchemicalanalysisandbioactivityassay |